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SUMMARY
Differentiation events contribute to phenotypic cellular heterogeneity within tumors and influence disease progression and response to therapy. Here, we dissect mechanisms controlling intratumoral heterogeneity within triple-negative basal-like breast cancers. Tumor cells expressing the cytokeratin K14 possess a differentiation state that is associated with that of normal luminal progenitors, and K14-negative cells are in a state closer to that of mature luminal cells. We show that cells can transition between these states through asymmetric divisions, which produce one K14 + and one K14 À daughter cell, and that these asymmetric divisions contribute to the generation of cellular heterogeneity. We identified several regulators that control the proportion of K14 + cells in the population. EZH2 and Notch increase the numbers of K14 + cells and their rates of symmetric divisions, and FOXA1 has an opposing effect. Our findings demonstrate that asymmetric divisions generate differentiation transitions and heterogeneity, and identify pathways that control breast cancer cellular composition.
INTRODUCTION
Cellular heterogeneity is observed in many tumor types and represents a major hurdle for effective therapy (Marusyk et al., 2012; Meacham and Morrison, 2013) . Transitions between differentiation states are thought to contribute to phenotypic intratumoral heterogeneity. In breast cancer, subpopulations of stem-like tumor cells possessing self-renewal and differentiation capacity have been identified (Brooks et al., 2015) . Recent studies suggest that, rather than following a unidirectional differentiation hierarchy, cancer cells are able to transition between stem-like and differentiated identities and can also exist in intermediate states (Chaffer et al., 2013; Patel et al., 2014; Roesch et al., 2010) . Cancer cell populations were shown in some cases to reach stable equilibria between phenotypically distinct subpopulations, suggesting the existence of dynamics and regulators that influence cellular composition (Quintana et al., 2010; Gupta et al., 2011) .
Lineage programs active in the normal mammary epithelium contribute to breast cancer cell differentiation state (Visvader and Stingl, 2014; Prat and Perou, 2011; Granit et al., 2014) . The mammary epithelium contains basal cells (also termed myoepithelial), some of which possess the potential to function as mammary stem cells (MaSCs), as well as luminal progenitors and mature luminal cells (Visvader and Stingl, 2014) . These cell types possess distinct traits and appear to include further cell subclasses (Shehata et al., 2012; Tornillo and Smalley, 2015; Fu et al., 2017 , Wang et al., 2017 . Breast cancer subtypes reflect these normal differentiation states: luminal, estrogen receptor (ER)-positive tumors express a gene signature associated with mature luminal cells, whereas basal-like breast cancers (which are mostly included in the triple-negative pathological group) express the signature of luminal progenitor cells and likely originate from them (Lim et al., 2009; Keller et al., 2012; Molyneux et al., 2010) .
Basal-like tumor cells may possess a high degree of plasticity, allowing them to transition between basal, progenitor, and luminal states. A hallmark of these triple-negative breast cancers (TNBCs) is that they contain cells expressing basal keratins, such as K5 and K14, often together with luminal keratins such as K8 and K18 (Prat and Perou, 2011; Badve et al., 2011) , consistent with such plasticity. Cells displaying a partially mesenchymal state, which have likely undergone a partial epithelial-to-mesenchymal transition (EMT), are also present in these tumors (Yu et al., 2013) . This high level of heterogeneity and apparent plasticity likely contribute to the aggressive nature of TNBCs and to the difficulty in their treatment. However, a detailed delineation of the differentiation states of cell subpopulations within these tumors, and of the mechanisms driving transitions between them, is lacking.
Here, we study lineage-associated differentiation transitions within triple-negative basal-like tumors and their contribution to cellular heterogeneity. We show that the K14-expressing subpopulation displays enhanced tumorigenicity associated with increased expression of a luminal-progenitor gene signature, whereas K14-negative cells display a more mature luminal state. We show that tumor cells can transition between these states through asymmetric divisions that generate distinct daughter cells and that this contributes to the generation of heterogeneity. We identify regulators that control the proportions of K14 + cancer cells and that modulate the relative rates of symmetric and asymmetric divisions.
RESULTS

Heterogeneity in Cellular Differentiation State within Basal-like Breast Cancers
We examined the degree of cellular heterogeneity in a collection of triple-negative, basal-like breast cancers (Table S1 ) by costaining for the luminal cytokeratin K18, the basal cytokeratin K14, and the mesenchymal marker vimentin (VIM). As expected, basal-like tumors exhibited heterogeneous staining patterns, with cells, often in close proximity, displaying different levels of these markers and their combinations ( Figures 1A and 1B , and 7.6% co-expressed K14). Similar heterogeneity was observed, to varying degrees, in several patient-derived xenografts (PDXs) of TNBCs ( Figure S1A ). We found that basal-like cell lines, specifically those maintaining epithelial identity (termed ''basal A''), retain some of this cellular heterogeneity and harbor three prominent subpopulations: K18 + ; K18 + K14 + ; and K18 + VIM + cells ( Figures 1C, 1D , and S1B).
We isolated and profiled the transcriptomes of these three subpopulations from two cell lines (HCC70 and MDA-MB-468) and assessed whether they differ in their expression of gene signatures of normal human mammary cell types (Lim et al., 2009; Shehata et al., 2012; Figures S1C and S1D;  Table  S2 ). The K18 + VIM + subpopulation showed the highest correlation with an EMT signature (Taube et al., 2010) as well as with the basal (MaSC) signature, consistent with a partially mesenchymal state and its association with normal basal cells (Ye et al., 2015) . We also found that K18 + K14 + cells isolated from a human triple-negative PDX expressed luminal progenitor signature genes at higher levels than K18 + K14 À cells ( Figure 1F to the necessity of cell fixation for keratin staining, we used a previously described reporter construct, in which GFP is driven by the K14 promoter (Granit et al., 2013 ; Figure S2B ). GFP high cells isolated from HCC70 and HCC1937 lines infected with this reporter were enriched for K14 + cells relative to the GFP À population by 1.5-to 2.5-fold, with no change in K18, which is expressed in nearly all cells ( Figures S2C-S2G ). The GFP high cells showed enhanced tumor formation and tumor growth rates relative to GFP À cells ( Figures 2C-2E ), supporting the notion that the K18 + K14 + subpopulation possesses enhanced tumorigenicity.
Basal-like Breast Cancer Cells Undergo Asymmetric Divisions
We next asked whether transitions of tumor cells between differentiation states could be directly detected. Asymmetric cell divisions, in which the two daughter cells differ in phenotype from one another, provide a mechanism for differentiation transitions (Morrison and Kimble, 2006) . To test whether asymmetric divisions occur in basal-like breast cancer cell populations, we conducted a bromodeoxyuridine (BrdU) pulse-chase assay: we treated sparsely seeded HCC70 cells with BrdU to label cells in S phase, waited 18-24 hr to allow generation of BrdU-labeled mitotic cell doublets, and then fixed and stained the cells for BrdU, K14, and K18 ( Figure 3A ). Pairs of BrdU + cells that were closely positioned in isolation from other cells and showed identical BrdU staining patterns were scored as mitotic products ( Figure 3B ). As expected, such doublets were rare when cells were fixed immediately after BrdU treatment ( Figure S3A ). We found that the majority of HCC70 cell divisions were symmetric, producing daughter cells that were either both K14 À or both K14 + (all co-expressing K18); however, $9% of cell divisions were asymmetric, giving rise to one K14 À and one K14 + daughter cell ( Figures 3B and 3C ). Other basal-like lines showed a similar distribution of division types, with somewhat lower rates of Figure S1 and Tables S1 and S2. asymmetric divisions ( Figures 3C and 3D ). Genomic sequencing of K18 + K14 À and K18 + K14 + HCC70 cell subpopulations did not reveal any copy number variations or changes in DNA methylation in the KRT14 gene ( Figures S3B and S3C ), indicating that the observed plasticity in K14 staining is independent of these genomic alterations.
To further establish the asymmetric nature of the observed divisions, we tested the distribution of additional differentiation markers together with K14. We found that ALDH1A1, a known marker of stem and progenitor cells (Ginestier et al., 2007) , was asymmetrically expressed in 9 of 16 divisions in which K14 was asymmetrically distributed but in none of 240 symmetric divisions (p < 10 À10 hypergeometric test), and in all cases, it was the K14 + daughter cell that also expressed ALDH1A1 ( Figure 3E ).
We next tested whether asymmetric divisions occur within patient-derived tumors. We injected BrdU into mice carrying a PDX from a triple-negative breast cancer that contained K18 + and K18 + K14 + cells (PDX06; Figure S1A ) and sacrificed them the following day. To detect mitotic cell pairs, tumor sections were stained for BrdU, K18, and K14. This revealed the presence of both symmetric and asymmetric divisions in the tumor, with asymmetric divisions that produced one K14 + and one K14 À cell (co-expressing K18) representing 10.6% of divisions (Figures 3F and 3G) . Very few BrdU + cell doublets were found in mice sacrificed on the day of BrdU treatment ( Figure S3D ). These findings indicate that asymmetric divisions occur within basallike breast cancer cell populations, generating K14-expressing and non-expressing cells.
Transitions in K14 Expression Generate Heterogeneity
To test the role of transitions between the K14 + and K14 À states in generating heterogeneity, we studied tumorspheres formed by HCC70 cells. If all divisions were symmetric and no transitions occurred, monoclonal tumorspheres would all be homogeneous, containing only K14 À or K14 + cells. However, every asymmetric division would generate a heterogeneous sphere containing both cell types. Thus, the occurrence of asymmetric divisions would be expected to produce an increasing percentage of heterogeneous spheres. All values indicate mean ± SEM. *p < 0.05; **p < 0.005; ***p < 0.0005; t test. See also Figure S2 . progenitor identity in the normal breast (Michalak et al., 2013) . We next tested the influence of EZH2 inhibition on symmetric and asymmetric division rates. We found that the percentage of asymmetric divisions in cells following shRNA silencing of EZH2 was more than double that of control cells, whereas the percentage of symmetric K14 + divisions was decreased ( Figure 5D ).
Similar changes were observed in GSK-126-treated cells (Figure 5E ). EZH2 silencing in HCC1937 cells also increased asymmetric division rates ( Figure 5F ). Table S4 ). shRNA vectors targeting the gene encoding K14 itself, used as a positive control, showed the expected reduction in K14 + cells ( Figure S5A ). Following a second screening step in which candidates were retested with multiple hairpins ( Figure S5C ), we identified four transcription factors whose silencing with multiple independent shRNAs consistently changed the fraction size of K18 + K14
+ cells in HCC70 cells (Figure 6B) , and these showed similar effects also in HCC1937 cells ( Figure 6C ). Factors whose silencing led to reduced K18 + K14 + fractions included KLF5, a regulator of embryonic stem cell identity, with a suggested oncogenic role in breast cancer (Jiang et al., 2008; Jia et al., 2016) ; NFIB, an oncogenic transcription factor that is often translocated in adenoid cystic breast carcinomas (Persson et al., 2009; Dooley et al., 2011) ; and RBPJ, the transcriptional mediator of Notch signaling (Koch et al., 2013) . Silencing of FOXA1, a known regulator of mammary ductal growth that is highly expressed in luminal cells and luminal subtype tumors (Bernardo and Keri, 2012) , had the opposite effect, increasing K18 + K14 + cell numbers ( Figures 6B and 6C ). To further verify their effects, we overexpressed these regulators in HCC70 cells. Overexpression of NFIB and KLF5 led to an increase in K18 + K14 + cell numbers, and FOXA1 overexpression reduced these numbers, consistent with the converse consequences of their silencing ( Figure 6D ). RBPJ overexpression did not increase K18 + K14 + cell numbers, likely due to the absence of enhanced upstream Notch signaling (Castel et al., 2013) . mRNA sequencing (mRNA-seq) of cells in which each regulator was silenced indicated that the factors whose silencing reduced K18 + K14 + cell numbers also reduced the expression of the luminal progenitor signature (Figures 6E and S5D ; Table S5 ). NFIB, KLF5, and RBPJ-silenced cells also showed increased expression of the basal signature, suggesting that these factors promote luminal progenitor identity at the expense of basal identity.
Silencing of FOXA1 increased the expression of the luminal progenitor signature ( Figure 6E ). FOXA1 mRNA levels are variable in basal-like breast cancers and are negatively correlated with KRT14 and EZH2 expression ( Figures S6A and S6B) . FOXA1 expression was increased in EZH2-silenced cells (Figure S6C) , consistent with these two regulators having opposing roles. We therefore tested the effects of FOXA1 silencing on symmetric and asymmetric division rates. Figures 7A and 7B) . Silencing of NOTCH1, or treatment with the g-secretase inhibitor (GSI) LY-411575, had a similar effect on population composition, Notch target genes, and lineage genes ( Figures 7C, 7D , and S7A-S7C). Conversely, NOTCH1 overexpression led to a dramatic increase in K18 + K14 + numbers in both HCC70 and HCC1937 cells ( Figures 7E, 7F , and S7D). Notch activity thus promotes the K18 + K14 + identity. Interestingly, RBPJ silencing led also to a dramatic decrease in tumor formation by HCC70 cells (Figure S7E) , highlighting a pro-tumorigenic function of this transcription factor.
Silencing of either NOTCH1 or RBPJ led to reduced numbers of symmetric K14 + divisions and to increased numbers of symmetric K14 À divisions ( Figure 7G ). Interestingly, unlike EZH2 inhibition, asymmetric division rates were also reduced. NOTCH1 overexpression exerted the opposite effect, increasing symmetric K14 + divisions as well as asymmetric division rates (Figure 7H) . Notch therefore appears to primarily promote symmetric K14 + divisions at the expense of K14 À symmetric divisions.
In light of their similar effects, we tested the regulatory relationship between EZH2 and Notch. We found that cells treated with the EZH2 inhibitor expressed reduced levels of Notch receptors and targets ( Figure 7I ). EZH2 levels were, however, unchanged in GSI-treated or NOTCH1-silenced cells ( Figure S7F ), suggesting that EZH2 acts upstream to Notch in this context, consistent with previous work (Gonzalez et al., 2014) . Indeed, treatment of RBPJ-silenced cells with GSK-126 did not further reduce K18 + K14 + cell numbers ( Figure 7J ).
We also tested whether NFIB, which promotes K18 + K14 + cell numbers, influences Notch. NFIB is expressed preferentially in basal-like breast cancers and in normal luminal progenitor and basal cells ( Figures S7G and S7H ). Cells silenced for NFIB expressed reduced levels of Notch receptors and targets, but not of EZH2 ( Figure 7K ), suggesting that it acts upstream to Notch, independently of EZH2. Consistent with this, most genes deregulated in RBPJ-silenced cells were also deregulated by NFIB silencing ( Figure S5D ). GSI treatment led to a significant reduction in K18 + K14 + cell numbers in NFIB-silenced cells, and GSK-126 had a more modest effect ( Figure 7L ). Together, these results suggest that Notch is a dominant regulator of K18 + K14
+ cell numbers and of asymmetric division rates and that it is positively regulated by both EZH2 and NFIB, whereas FOXA1 exerts an opposite effect ( Figure 7M ). Figure S4 and Table S3 .
DISCUSSION
Accumulating evidence indicates that non-genetic mechanisms substantially contribute to cellular heterogeneity within tumors and thereby to disease progression and resistance to therapy (Marusyk et al., 2012; Meacham and Morrison, 2013; Jordan et al., 2016; Roesch et al., 2010) . The ability of cells to transition between differentiation states and adopt intermediate identities can generate a wide spectrum of cell phenotypes. Past analyses of basal-like breast tumor transcriptomes revealed the association of this subtype with luminal progenitor cells (Lim et al., 2009 ). However, the high level of cellular heterogeneity observed in these cancers suggests that they may often contain cells in a variety of differentiation states. We show here that some of these tumor cells possess an identity closer to that of luminal progen- The association of the K18 + K14 + profile with normal luminal progenitor identity is consistent with previous demonstrations of basal keratin expression in progenitor cells (Lim et al., 2009; Chakrabarti et al., 2012; Prat and Perou, 2011) . Other markers used to identify luminal progenitors, such as CD49f, EpCAM, and ALDH1 (Visvader and Stingl, 2014; Smalley et al., 2012; Brooks et al., 2015) , may allow for further enrichment of progenitor-like cells from these tumors. Recent studies suggest that several types of progenitors exist in the luminal compartment (Shehata et and S6 and Tables S3, S4 , and S5.
(legend on next page) 2017), and, therefore, different progenitor-like cell types may exist in tumors, with the K18 + K14 + profile enriching for a particular subset. Co-expression of basal and luminal programs is observed in embryonic mammary precursors and in cell subsets of the postnatal prepubertal mouse gland Wuidart et al., 2018) + cells are present in the invasive edges and metastases of breast cancers (Cheung et al., 2013) and with work showing increased expression of basal and progenitor markers in individually seeded metastatic cells (Lawson et al., 2015) . The processes allowing cancer cells to transition from one state to another are overall poorly characterized, and it is not clear whether such transitions are dependent on cell division. Asymmetric divisions represent one mechanism tying cell division to differentiation (Morrison and Kimble, 2006) , and their occurrence has been shown in cell populations of several cancer types, including glioma, colon, and breast (Cicalese et al., 2009; Sugiarto et al., 2011; Bu et al., 2013) . We directly show asymmetric divisions occurring within basal-like cell populations, producing one K14 + and one K14 À daughter cell. The detection of asymmetric divisions in a patient-derived xenograft provides indication that such divisions occur within tumors. Our finding that cellular heterogeneity progressively develops in growing monoclonal tumorspheres and that asymmetric divisions can be detected within them supports the notion that such divisions play a role in generating cellular heterogeneity through transitions between K14 + and K14 À states. We were not able to directly determine the identities of the mother cells of individual divisions due to the need for cell fixation to detect keratins. However, our findings suggest that both cell types are able to transition. The ability to detect asymmetric divisions involving K14 may be related to the observation that cytokeratin filaments disintegrate during cytokinesis and are distributed between daughter cells prior to reassembly (Lane et al., 1982) . Indeed, when cytokinesis was inhibited by blebbistatin, we could not detect cell pairs with asymmetric K14 distribution (data not shown). Asymmetric keratin distribution has also been observed in colon cancer cells (Bu et al., 2013) .
We identify several regulators that control the percentage of K14 + cells and thereby the composition of the tumor cell population: EZH2, Notch, KLF5 and NFIB act to increase the numbers of these cells, and their silencing leads to a new equilibrium in which the numbers of these cells are reduced. In contrast, FOXA1 and, as we have previously shown, GATA3 (Granit et al., 2013) , perform the opposite function and are inhibited by EZH2. This is consistent with known roles of EZH2 and Notch in promoting luminal progenitor proliferation and function in the normal gland and the roles of FOXA1 and GATA3 in determining luminal identity (Michalak et al., 2013; Bouras et al., 2008; Bernardo and Keri, 2012) . KLF5 and NFIB, although known to play other roles in breast cancer or in differentiation (Jiang et al., 2008; Jia et al., 2016; Persson et al., 2009; Dooley et al., 2011) , were not previously linked with regulation of breast cancer cell identity. We show that EZH2, Notch, and FOXA1 influence the relative rates of symmetric and asymmetric divisions. The combined levels of activity of these regulators and others may thus determine the overall balance between division types, leading to a particular cellular composition.
Notch is known to regulate mammary differentiation and division symmetry in a variety of settings (Koch et al., 2013; Bouras et al., 2008; Harrison et al., 2010) . We show that Notch is positively regulated by EZH2, consistent with previous work (Gonzalez et al., 2014) , as well as by NFIB. Previous studies have implicated Notch and its target and negative regulator Numb in regulation of asymmetric divisions, and p53 and miR-34 have been linked to their activity (Bu et al., 2013; Tosoni et al., 2015) . We could not detect asymmetric expression of Numb, Figure S7 and Table S3 .
but other related components of this network may influence Notch activity in the context described here. Together, our findings shed light on the regulation of cellular heterogeneity and differentiation state in basal-like breast cancers and highlight several transcription factors that influence population composition. Manipulation of tumor composition can be achieved by pharmacologic means, including inhibitors of EZH2 and Notch, currently undergoing clinical evaluation. This supports the validity of approaches aimed at modulating cancer cell differentiation state, and thereby manipulating the cellular composition of tumors, as a component of treatment. Cell Division Symmetry Assay and Tumorspheres Cells were filtered twice through a 40-mm strainer and seeded sparsely on chambered cover slides (IBD-80826; Ibidi). 24 hr after seeding, the cells were treated for 2 hr with 10 mg/mL BrdU (Sigma-Aldrich) and 18-24 hr subsequently were fixed with cold ethanol and treated with 1M HCl. Residual acid was neutralized with 0.1M sodium tetraborate (Na 2 B 4 O 7 ) (pH = 8.5), and cells were stained for BrdU, K14, and K18 or ALDH1A1, using PBS + 10% fetal calf serum (FCS) for antibody suspension (2% FCS for washes), and with conjugated secondary antibodies. In experiments testing the effects of gene silencing, cells were seeded 4 days after infection with the appropriate shRNA lentivirus. Treatment of cells with Notch or EZH2 inhibitor was conducted for 3 days, starting one day before seeding. Stained cells were imaged and scored using a confocal microscope. Only cell doublets that showed identical BrdU stain pattern and were distant from other cells were scored. For detection of heterogeneity and asymmetric divisions in HCC70 tumorspheres, 6,000 cells were seeded after filtration in chambers coated with growth-factor-reduced Matrigel (cat no. 356230; Corning). Tumorspheres were grown for 3-6 days. Spheres were treated for 2 hr with 10 mg/mL BrdU one day prior to fixation and stained as above for BrdU, K14, and E-cadherin. For quantification of the percentage of polyclonal spheres, we seeded under this protocol a 1:1 mixture of HCC70 cells stably expressing GFP or mCherry and scored the percentage of spheres showing both colors, indicating polyclonality.
Tumor Transplantation and BrdU Labeling
For tumor-seeding experiments, HCC70 or HCC1937 cells infected with the K14p-GFP vector were sorted for GFP high and GFP À fractions by FACS, and cells were counted and injected in 10 mL culture medium containing 25% Matrigel (BD Biosciences) into no. 4 mammary glands of 6-week-old female non-obese diabetic (NOD)-severe combined immunodeficiency (SCID) (NOD; Prkdc scid ) or NSG mice as indicated. Tumors were measured externally by calipers and monitored for up to 5 months. Lack of tumor formation was validated by excision of the mammary gland. To evaluate the metastatic presence of K18 + K14 + cells, 1 3 10 6 GFP-labeled MDA-MB-468 cells were suspended in 25% Matrigel in media, injected into no. 4 mammary glands of 6-week-old female NSG mice, and allowed to form tumors for 3 months. For lung-seeding experiments, 1 3 10 6 GFP-labeled MDA-MB-468 cells were suspended in 100 mL F12 media and injected into the tail vein of NSG female mice.
Primary tumors and lung sections were stained for K14, K18, and GFP. The percentage of K18 + K14 + cells among GFP + cells was scored by image analysis using the CellProfiler software. For growth of patient-derived tumors, samples were minced and implanted into both no. 4 mammary glands of 6-week-old female NSG mice in 100 mL 50% Matrigel. Tumors were extracted 3-9 weeks after transplantation, minced, and suspended in media containing collagenase A (Roche; 1.5 mg/mL); incubated for 1 hr in a 37 C rocker; filtered through a 40-mM strainer; and stained and sorted to isolate K18 + and K18 Statistical Methods p values were mostly calculated using two-sided Student's t test as indicated. For comparisons of symmetric and asymmetric division distributions, a chi-square test was used. Significance of tumor-initiating experiments was done using extreme limiting dilution analysis (ELDA) (Hu and Smyth, 2009 ). The tumor diversity index was calculated using the Shannon-Wiener index
pi 3 piÞ.
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